C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
First Claim
Patent Images
1. An oligonucleotide comprising a sequence complementary to an mRNA from a c-myc gene, wherein the nucleoside subunits of the oligonucleotide are joined by intersubunit linkages, wherein at least one of the intersubunit linkages is a thiophosphoramidate linkage, wherein the oligonucleotide is about 6 to about 30 nucleotides in length and comprises a sequence selected from the group consisting of AACGTTGAGGGGCAT (SEQ ID NO:
- 1), UAACGTTGAGGGGCA (SEQ ID NO;
2), TAACGTTGAGGGGCAT (SEQ ID NO;
3), TTTCATTGTTTTCCA (SEQ ID NO;
4), CTCGTCGTTTCCGCAACAAG (SEQ ID NO;
6), ACGTTGAGGGGCATCGTCGC (SEQ ID NO;
7), AACGTTGAGGGGCATCGTCG (SEQ ID NO;
8), CTGCTGTCGTTGAGAGGGTA (SEQ ID NO;
9), GGCATCGTCGCGGGAGGCTGCTGGAGCG (SEQ ID NO;
10), GGCATCGTCGCGGGAGGCTG (SEQ ID NO;
11), TCGTCGCGGGAGGCTGCTGG (SEQ ID NO;
12), CCGCCCGCTCGCTCCCTCTG (SEQ ID NO;
13), GTTCTCCTCCTCGTCGCAGT (SEQ ID NO;
14), ACGTTGAGGGGCAT (SEQ ID NO;
15) and TCGTCGCGGGAGGCTG (SEQ ID NO;
16), and wherein the oligonucleotide, when bound to the mRNA in a cell, prevents translation of the mRNA by steric hindrance.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.
32 Citations
36 Claims
-
1. An oligonucleotide comprising a sequence complementary to an mRNA from a c-myc gene, wherein the nucleoside subunits of the oligonucleotide are joined by intersubunit linkages, wherein at least one of the intersubunit linkages is a thiophosphoramidate linkage, wherein the oligonucleotide is about 6 to about 30 nucleotides in length and comprises a sequence selected from the group consisting of AACGTTGAGGGGCAT (SEQ ID NO:
- 1), UAACGTTGAGGGGCA (SEQ ID NO;
2), TAACGTTGAGGGGCAT (SEQ ID NO;
3), TTTCATTGTTTTCCA (SEQ ID NO;
4), CTCGTCGTTTCCGCAACAAG (SEQ ID NO;
6), ACGTTGAGGGGCATCGTCGC (SEQ ID NO;
7), AACGTTGAGGGGCATCGTCG (SEQ ID NO;
8), CTGCTGTCGTTGAGAGGGTA (SEQ ID NO;
9), GGCATCGTCGCGGGAGGCTGCTGGAGCG (SEQ ID NO;
10), GGCATCGTCGCGGGAGGCTG (SEQ ID NO;
11), TCGTCGCGGGAGGCTGCTGG (SEQ ID NO;
12), CCGCCCGCTCGCTCCCTCTG (SEQ ID NO;
13), GTTCTCCTCCTCGTCGCAGT (SEQ ID NO;
14), ACGTTGAGGGGCAT (SEQ ID NO;
15) and TCGTCGCGGGAGGCTG (SEQ ID NO;
16), and wherein the oligonucleotide, when bound to the mRNA in a cell, prevents translation of the mRNA by steric hindrance. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- 1), UAACGTTGAGGGGCA (SEQ ID NO;
- 19. An oligonucleotide comprising a sequence complementary to an mRNA from a c-myc gene, wherein the nucleoside subunits of the oligonucleotide are joined by intersubunit linkages, wherein the oligonucleotide comprises a sequence of singly alternating intersubunit linkages A and B that is about 6 to about 30 nucleotides in length wherein each A is a thiophosphoramidate or phosphoramidate intersubunit linkage and each B is a thiophosphate or phosphate intersubunit linkage, and wherein the oligonucleotide, when bound to the mRNA in a cell, is a substrate for RNase-H-mediated degradation of the mRNA from a c-myc gene or wherein the oligonucleotide, when bound to the mRNA in a cell, prevents translation of the mRNA by steric hindrance.
Specification